Call (844) 879-2237

Home » FSS » Acera Surgical Awarded Federal Supply Schedule (FSS) Contract for Restrata® Wound Matrix

Acera Surgical Awarded Federal Supply Schedule (FSS) Contract for Restrata® Wound Matrix

St. Louis, MO, August 8, 2018 – Acera Surgical, a leader in implantable nanomedical scaffolds, announced today that the National Acquisition Center of the Department of Veterans Affairs has awarded the company a Federal Supply Schedule (FSS) contract, effective August 15, 2018 through August 14, 2023.  The FSS contract will allow government facilities, including those operated by the U.S. Department of Veterans Affairs (VA), the Department of Defense (DoD), the Bureau of Indian Affairs, and the Federal Bureau of Prisons, to have easy access to the Restrata® Wound Matrix.

Restrata® Wound Matrix is a nanomedical scaffold that exhibits structural attributes similar to native human extracellular matrix (ECM), supporting cellular ingrowth, differentiation, and retention, as well as vascularization.  It is offered in a range of sizes for use in partial and full-thickness wounds, acute and chronic wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneling wounds, surgical wounds, trauma wounds (e.g., partial thickness burns), and exudating wounds.

“We are honored to be awarded this FSS contract, which will allow us to expand clinical access to the Restrata® Wound Matrix to all government institutions, including those serving our veterans,” said Dr. Matthew MacEwan, Co-Founder and Chief Scientific Officer of Acera Surgical.  “The government’s decision to add Restrata to the Federal Supply Schedule is a significant step forward in the execution of our commercial strategy.”

The Veterans Health Administration operates the nation’s largest integrated health care system with more than 1,700 health-care facilities across the country and serves nine million enrolled veterans annually.

 

About Acera Surgical Inc.

Acera Surgical Inc.  (“Acera,” St. Louis, Missouri) is a bioscience company commercializing a portfolio of implantable nanomedical scaffolds for regenerative medical applications.  Acera’s products exhibit a structure similar to native extracellular matrix (ECM) and support effective healing. Acera is currently commercializing its first two products, the Cerafix® Dural Substitute and the Restrata® Wound Matrix, both FDA cleared via 510(k).

For additional information on Acera Surgical or the Restrata® Wound Matrix, please visit www.acera-surgical.com.

 

Comments are closed.